Study summary
Lenvatinib plus pembrolizumab controlled previously treated thymic cancers in most people
88.4%had no cancer growth at 5 months
What was tested
Lenvatinib, a targeted pill, with pembrolizumab, in B3 thymoma or thymic carcinoma that had grown after chemotherapy. No comparison group.
What they found
- At 5 months, 88.4% had no growth of their cancer.
- Serious treatment-related side effects occurred in 37%; serious immune side effects in 14%, including one case each of heart and brain inflammation.
What it means
A candidate standard after chemotherapy, with careful monitoring for immune side effects.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.